β-defensin 26 Inhibitors
β-defensin 26 inhibitors represent a specific class of chemical compounds designed to modulate the activity of β-defensin 26 (BD-26), a member of the defensin family of antimicrobial peptides. β-defensins are small, cationic peptides predominantly produced by epithelial cells, and they are known to play a role in various biochemical pathways related to immune and cellular responses. Structurally, β-defensins are characterized by their three disulfide bridges, which confer a specific three-dimensional configuration that is critical to their function. β-defensin 26, in particular, shares this structural signature but has unique sequences and properties that distinguish it from other β-defensins. Inhibitors of β-defensin 26 are typically designed to interact with this peptide's active or binding sites, altering its biochemical interactions. The inhibitors can be small molecules, peptides, or even larger macromolecules depending on the specific approach taken to block or modify the function of BD-26.
From a chemical perspective, β-defensin 26 inhibitors may work by preventing the binding of β-defensin 26 to its target molecules or by altering the peptide's conformation in a way that disrupts its activity. The development of these inhibitors requires a deep understanding of the structural and dynamic aspects of β-defensin 26, including the detailed mapping of its functional domains and key amino acid residues involved in molecular recognition and binding. The design of effective inhibitors often involves computational modeling, structure-activity relationship (SAR) studies, and biophysical methods to assess the interaction strength and specificity of the inhibitors. Techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy are often employed to visualize how these inhibitors bind to β-defensin 26, providing insights into optimizing their chemical structures for greater specificity and activity within the context of the biochemical processes they are intended to influence.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
SIRT1 activator impacting β-defensin 26 indirectly. Resveratrol activates SIRT1, leading to deacetylation of NF-κB. This event inhibits NF-κB activation, suppressing β-defensin 26 expression by preventing its transcriptional regulation through the NF-κB pathway. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
p38 MAPK inhibitor affecting β-defensin 26 through the p38 MAPK pathway. SB203580 inhibits p38 MAPK, disrupting downstream signaling events. By preventing p38-mediated events, it alters the transcriptional regulation of β-defensin 26 in response to extracellular signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor influencing β-defensin 26 through the mTOR pathway. Rapamycin inhibits mTOR, disrupting downstream signaling events. This interference alters the translation and transcription processes associated with β-defensin 26 regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor affecting the PI3K/Akt pathway. By blocking Akt activation, LY294002 indirectly influences β-defensin 26 expression. This disruption of the PI3K pathway alters downstream signaling events, leading to the downregulation of β-defensin 26. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor inhibitor impacting the TGF-β signaling pathway. SB431542 indirectly downregulates β-defensin 26 by blocking TGF-β receptor activation. This prevents the transduction of signals that would otherwise contribute to β-defensin 26 regulation. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
AMPK activator influencing β-defensin 26 through the AMPK pathway. A769662 activates AMPK, which then inhibits mTOR. This cascade of events alters the translation and transcription processes associated with β-defensin 26, leading to its downregulation. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $153.00 $332.00 | 59 | |
JAK inhibitor impacting β-defensin 26 through the JAK/STAT pathway. By inhibiting JAK, it disrupts downstream STAT activation, altering the transcriptional regulation of β-defensin 26. The inhibition of JAK prevents the events that contribute to β-defensin 26 upregulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor influencing β-defensin 26 through the JNK pathway. SP600125 inhibits JNK, leading to altered transcriptional regulation of β-defensin 26. By preventing c-Jun phosphorylation, a downstream target of JNK, it downregulates β-defensin 26 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Selective MEK inhibitor impacting β-defensin 26 through the MAPK/ERK pathway. PD98059 inhibits MEK, disrupting downstream ERK activation. This interference alters the transcriptional regulation of β-defensin 26 in response to extracellular signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor influencing β-defensin 26 through the PI3K/Akt pathway. Wortmannin inhibits PI3K, blocking Akt activation and disrupting downstream signaling events. This alteration leads to the downregulation of β-defensin 26 at the transcriptional level. | ||||||